The prepared nanovaccines named 8FNs can reverse the immunosuppressive tumor microenvironment, induce robust antitumor CD8+ T cell responses, inhibit tumor growth and metastasis, and show a synergistic therapeutic effect with anti‐PD‐1 therapy. This evidence concerns the gene CD8A and neoplasm.